https://doctransparency.com/doctor/fl/oxford/saumilkumar-karavadia-1376747162
Medicare Enrolled

Dr. Saumilkumar Karavadia, MD

Urology Physician · Oxford, FL
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Speaking/Promotional
12109 CR 103, Oxford, FL 34484
3524300705
In practice since 2007 (18 years)
NPI: 1376747162 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Karavadia from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Karavadia? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Karavadia

Dr. Saumilkumar Karavadia is an urology physician in Oxford, FL, with 18 years in practice. Based on federal Medicare data, Dr. Karavadia performed 17,006 Medicare services across 5,686 unique beneficiaries.

Between the years covered by Open Payments, Dr. Karavadia received a total of $47,763 from 62 pharmaceutical and/or device companies across 590 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in urology physician. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Karavadia is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 18 years in practice▲ Top 7% volume in FL$ $47,763 industry payments

Medicare Practice Summary

Medicare Utilization ↗
17,006
Medicare services
Top 7% in FL for urology physician
5,686
Unique beneficiaries
$27
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~945 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Contrast dye for imaging (iodine-based)3,501$0$1
BCG treatment for bladder cancer3,250$2$5
Automated urinalysis2,563$2$5
Office visit, established patient (30-39 min)1,678$92$320
Leuprolide injectable, camcevi, 1 mg966$68$130
Bladder ultrasound after voiding879$8$26
Blood draw (venipuncture)809$6$6
Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml747$1$3
Office visit, established patient (20-29 min)635$64$227
Chronic care management, first 20 min/month379$47$159
New patient office visit (45-59 min)249$117$422
X-ray of abdomen, 1 view247$21$60
Diagnostic exam of bladder and urethra using an endoscope210$61$610
Leuprolide acetate (for depot suspension), 7.5 mg161$136$336
Instillation of anti-cancer drug into bladder78$64$219
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle76$24$81
Simple insertion of temporary bladder tube55$44$156
Mri scan of pelvis before and after contrast48$125$354
Ct scan of abdomen and pelvis without contrast48$76$216
Mri scan of abdomen before and after contrast46$147$386
Ct scan of abdomen and pelvis before and after contrast42$195$527
Insertion of stent in ureter using an endoscope37$134$599
Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope36$115$809
Crushing of stone of ureter with insertion of stent using an endoscope34$325$1,061
Hospital follow-up visit, moderate complexity30$64$179
Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional29$16$57
Initial hospital admission, moderate complexity27$104$341
Shock wave crushing of kidney stones26$443$1,460
Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope22$584$1,866
Ultrasound scan of pelvic region through rectum20$26$93
Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm18$223$735
Exam with injections of chemical for destruction of bladder using an endoscope16$138$992
Biopsy of prostate gland16$106$612
New patient office visit (30-44 min)15$87$283
Dilation of urethra using an endoscope13$118$798
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.6% high complexity
32.0% medium
67.4% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$47,763
Total received (2018-2024)
Avg $6,823/year across 7 years
Top 6% in FL for urology physician
62
Companies
590
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$32,656 (68.4%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$13,512 (28.3%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,596 (3.3%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$8,289
2023
$7,113
2022
$10,423
2021
$2,148
2020
$8,019
2019
$4,608
2018
$7,165

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Astellas Pharma US Inc
$29,059
PFIZER INC.
$4,595
Intuitive Surgical, Inc.
$1,901
Astellas Pharma Global Development
$1,596
Janssen Biotech, Inc.
$1,292
Myriad Genetic Laboratories, Inc.
$1,250
Medtronic USA, Inc.
$1,004
Bayer Healthcare Pharmaceuticals Inc.
$616
Sumitomo Pharma America, Inc.
$592
Axonics, Inc.
$387
AstraZeneca Pharmaceuticals LP
$377
Teleflex LLC
$320
Endo Pharmaceuticals Inc.
$303
Myovant Sciences Inc.
$292
UROVANT SCIENCES INC
$261
UROGEN PHARMA, INC.
$247
ABBVIE INC.
$244
Dendreon Pharmaceuticals LLC
$239
Novartis Pharmaceuticals Corporation
$225
Bayer HealthCare Pharmaceuticals Inc.
$207
Merck Sharp & Dohme LLC
$183
180 Medical, Inc.
$170
Antares Pharma, Inc.
$165
Blue Earth Diagnostics Limited
$161
PROCEPT BioRobotics Corporation
$143
SN Holdings, LLC
$140
Allergan Inc.
$135
Tolmar, Inc.
$128
Coloplast Corp
$101
Telix Pharmaceuticals
$90
Integra LifeSciences Corporation
$89
UroGen Pharma, Inc.
$88
Janssen Scientific Affairs, LLC
$82
Sun Pharmaceutical Industries Inc.
$79
Amgen Inc.
$76
BOSTON SCIENTIFIC CORPORATION
$66
ACCORD HEALTHCARE, INC.
$62
TOLMAR Pharmaceuticals, Inc.
$61
Olympus America Inc.
$61
Allergan, Inc.
$55
Ferring Pharmaceuticals Inc.
$54
Baxter Healthcare
$54
MEDIVATION FIELD SOLUTIONS LLC
$51
Verity Pharmaceuticals Inc.
$48
Smith+Nephew, Inc.
$46
Foundation Medicine, Inc.
$37
Axonics Modulation Technologies, Inc.
$35
Medtronic, Inc.
$31
AbbVie, Inc.
$31
Boston Scientific Corporation
$30
Rochester Medical Corporation
$25
Photocure Inc
$22
Accord Healthcare, Inc.
$20
COLOPLAST CORP
$20
Pacira Pharmaceuticals Incorporated
$17
Avadel Specialty Pharmaceuticals, LLC
$17
Ethicon US, LLC
$16
Travere Therapeutics, Inc.
$16
Metuchen Pharmaceuticals
$13
DENTSPLY IH Inc.
$13
Acerus Pharmaceuticals Corporation
$12
Cook Medical LLC
$11
Top 3 companies account for 74.4% of total payments
Associated products mentioned in payments ›
(815) Thiola · ADSTILADRIN · AFINITOR · ALTIS · AMS · AQUABEAM SYSTEM · AVEED · AXIS · Androgel · Axonics · Axonics r-SNM System · Axumin · BOTOX · BOTOX THERAPEUTIC · CAMCEVI · CYSVIEW · Cook Medical Holmium Laser Fiber · DA VINCI SP · DURASPHERE · Da Vinci Surgical System · ELIGARD · ERLEADA · EXPAREL · Enseal X1 5mm · Erleada · FOUNDATIONONE · GEMTESA · GENERAL ERECTILE DYSFUNCTION · GREENLIGHT · ILLUCCIX · INTERSTIM · JELMYTO · KEYTRUDA · LUPRON DEPOT · LYNPARZA · LoFric · MEDIHONEY · MYRBETRIQ · Myrbetriq · Natesto · Noctiva · Nubeqa · ORGOVYX · PERCLOT · PLUVICTO · POSLUMA · PROLARIS · PROVENGE · Porges Coloplast · Prolaris · Prolia · ReTrace · SOLESTA · STRAVIX · SUTENT · Stendra · Stravix · TISSEEL · TITAN · Trelstar · UROLIFT · UroLift System · XGEVA · XIAFLEX · XTANDI · XYOSTED · Xofigo · Xtandi · YONSA · ZYTIGA · iTIND System
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (68%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in urology physician and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 6% for urology physician in FL.

Equivalent to $281 per 100 Medicare services performed
Looking for a urology physician in Oxford?
Compare urology physicians in the Oxford area by procedure volume, costs, and industry payment transparency.
Browse urology physicians nearby

Geographic Context

Urology Physicians within 10 mi
32
Per 100K population
23.3
County median income
$73,297
Nearest hospital
VILLAGES REGIONAL HOSPITAL, THE
12.2 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Karavadia is a clinical cardiology specialist, with above-average Medicare volume (top 7% in FL), and high industry engagement (speaking/promotional, top 6%), with 18 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Karavadia experienced with contrast dye for imaging (iodine-based)?
Based on Medicare claims data, Dr. Karavadia performed 3,501 contrast dye for imaging (iodine-based) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Karavadia receive payments from pharmaceutical companies?
Yes. Dr. Karavadia received a total of $47,763 from 62 companies across 590 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Karavadia's costs compare to other urology physicians in Oxford?
Dr. Karavadia's average Medicare payment per service is $27. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Karavadia) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →